Secreted Klotho and chronic kidney disease

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 126-157

  Hu, Ming Chang ^a   Kuro O, Makoto ^a   Moe, Orson W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; ANTIOXIDANT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDICAN; ION CHANNEL; KLOTHO PROTEIN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAPAMYCIN; SCAVENGER; SODIUM PHOSPHATE COTRANSPORTER 3; TACROLIMUS; TROGLITAZONE; BETA GLUCURONIDASE;

ACUTE KIDNEY FAILURE; AGING; ANTI OXIDATION; ARTICLE; CALCIFICATION; CELL AGING; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLOMERULONEPHRITIS; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HORMONE INHIBITION; HUMAN; HYPERTENSION; IMMUNE MEDIATED CHRONIC GLOMERULONEPHRITIS; IMMUNE MEDIATED NEPHROTIC SYNDROME; ION TRANSPORT; KIDNEY FIBROSIS; KIDNEY INJURY; METABOLIC DISORDER; METABOLIC SYNDROME X; NEOVASCULARIZATION (PATHOLOGY); NEPHRECTOMY; NEPHROTIC SYNDROME; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHATE METABOLISM; PHOSPHATURIA; PHOSPHOTOXICITY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; UPREGULATION; VIRAL GENE THERAPY; VITAMIN D DEFICIENCY; ANIMAL; BIOSYNTHESIS; CHRONIC DISEASE; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SECRETION;

ANIMALS; CHRONIC DISEASE; DISEASE PROGRESSION; GLUCURONIDASE; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 84859522038     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_9     Document Type: Article

References (232)

1. Koh N, Fujimori T, Nishiguchi S et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001; 280(4):1015-1020
2. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22(1):124-136
3. Aizawa H, Saito Y, Nakamura T et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 1998; 249(3):865-871
4. Matsumura Y, Aizawa H, Shiraki-Iida T et al. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 1998; 242(3):626-630
5. Shiraki-Iida T, Aizawa H, Matsumura Y et al. Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett 1998; 424(1-2):6-10
6. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390(6655):45-51
7. Tohyama O, Imura A, Iwano A et al. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2004; 279(11):9777-9784
8. Chen CD, Podvin S, Gillespie E et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104(50):19796-19801
9. Bloch L, Sineshchekova O, Reichenbach D et al. Klotho is a substrate for alpha-, beta- and gamma-secretase. FEBS Lett 2009; 583(19):3221-3224
10. Huang CL. Regulation of ion channels by secreted Klotho: mechanisms and implications. Kidney Int 2010; 77(10):855-860
11. Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317(5839):803-806
12. Goetz R, Nakada Y, Hu MC et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad SciUSA2010; 107(1):407-412
13. Carpenter TO, Insogna KL, Zhang JH et al. Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment and Relationship to Parathyroid Status. J Clin Endocrinol Metab 2010; 95(11):E352-E357
14. Hu MC, Shi M, Zhang J et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renalproximal tubule. FASEB J 2010; 24(9):3438-3450
15. Cha SK, Hu MC, Kurosu H et al. Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho. Mol Pharmacol 2009; 76(1):38-46
16. Cha SK, Ortega B, Kurosu H et al. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad SciUSA2008; 105(28):9805-9810
17. Kato Y, Arakawa E, Kinoshita S et al. Establishment of the anti-Klotho monoclonal antibodies and detection ofKlotho protein in kidneys. Biochem Biophys Res Commun 2000; 267(2):597-602
18. Haruna Y, Kashihara N, Satoh M et al. Amelioration of progressive renal injury by genetic manipulation ofKlotho gene. Proc Natl Acad Sci USA 2007; 104(7):2331-2336
19. Saito Y, Nakamura T, Ohyama Y et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 2000; 276(2):767-772
20. Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309(5742):1829-1833
21. Mitani H, Ishizaka N, Aizawa T et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002; 39(4):838-843
22. Mitobe M, Yoshida T, Sugiura H et al. Oxidative stress decreases klotho expression in a mouse kidney cell line. Nephron Exp Nephrol 2005; 101(2):e67-e74
23. Sugiura H, Yoshida T, Tsuchiya K et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant 2005; 20(12):2636-2645
24. Chang Q, Hoefs S, van der Kemp AW et al. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005; 310(5747):490-493
25. Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxy vitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 2002; 143(2):683-689
26. Tsujikawa H, Kurotaki Y, Fujimori T et al. Klotho, a gene related to a syndrome resemblinghuman premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17(12):2393-2403
27. Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatr Nephrol 2010; 25(11):2241-2245
28. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117(12):4003-4008
29. Invidia L, Salvioli S, Altilia S et al. The frequency ofKlotho KL-VS polymorphism in a large Italian population, from young subjects to centenarians, suggests the presence of specific time windows for its effect. Biogerontology2010; 11(1):67-73
30. Zhang F, Zhai G, Kato BS et al. Association between KLOTHO gene and hand osteoarthritis in a female Caucasian population. Osteoarthritis Cartilage 2007
31. Rhee EJ, Oh KW, Lee WY et al. The differential effects of age on the association of KLOTHO gene polymorphisms with coronary artery disease. Metabolism 2006; 55(10):1344-1351
32. Rhee EJ, Oh KW, Yun EJ et al. Relationship between polymorphisms G395A in promoter and C1818T in exon 4 of the KLOTHO gene with glucose metabolism and cardiovascular risk factors in Korean women. J Endocrinol Invest 2006; 29(7):613-618
33. Nolan VG, Adewoye A, Baldwin C et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006; 133(5):570-578
34. Arking DE, Becker DM, Yanek LR et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003; 72(5):1154-1161
35. Arking DE, Krebsova A, Macek M Sr et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 2002; 99(2):856-861
36. Kawano K, Ogata N, Chiano M et al. Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res 2002; 17(10):1744-1751
37. Yu J, Deng M, Zhao J et al. Decreased expression of klotho gene in uremic atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2010; 391(1):261-266
38. Friedman DJ, Afkarian M, Tamez H et al. Klotho variants and chronic hemodialysis mortality. J Bone Miner Res 2009; 24(11):1847-1855
39. Saito K, IshizakaN, Mitani H et al. Iron chelation and a free radical scavenger suppress angiotensin II-induced downregulation ofklotho, an anti-aging gene, in rat. FEBS Lett 2003; 551(1-3):58-62
40. Cheng MF, Chen LJ, Cheng JT. Decrease of Klotho in the kidney of streptozotocin-induced diabetic rats. J Biomed Biotechnol 2010; 2010:513853
41. Han DH, Piao SG, Song JH et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression ofKLOTHO, an antiaging gene. Transplantation 2010; 90(2):135-141
42. Yoon HE, Ghee JY, Piao S et al. Angiotensin II blockade upregulates the expression ofKlotho the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011; 26(3):800-813
43. Yamazaki Y, Imura A, Urakawa I et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010; 398(3):513-518
44. Zuo Z, Lei H, Wang X et al. Aging-related kidney damage is associated with a decrease in klotho expression and an increase in superoxide production. Age (Dordr) 2010; Epub ahead of press
45. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117(9):2684-2691
46. Manya H, Akasaka-Manya K, Endo T. Klotho protein deficiency and aging. Geriatr Gerontol Int 2010; 10 Suppl 1:S80-S87
47. Brownstein CA, Adler F, Nelson-Williams C et al. A translocation causing increased alpha-klotho level results inhypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 2008; 105(9):3455-3460
48. Takeshita K, Fujimori T, Kurotaki Y et al. Sinoatrial node dysfunction and early unexpected death of mice with a defect ofklotho gene expression. Circulation 2004; 109(14):1776-1782
49. Imura A, Iwano A, Tohyama O et al. Secreted Klotho protein in sera and CSF: implication for posttranslational cleavage in release ofKlotho protein from cell membrane. FEBS Lett 2004; 565(1-3):143-147
50. Hu MC, Shi M, Zhang J et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010; 78 (12):1240-1251
51. Schramme A, Abdel-Bakky MS, Gutwein P et al. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int 2008; 74(3):328-338
52. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem 2008; 389(3):233-241
53. Huang BS, Leenen FH. Dietary Na, age and baroreflex control of heart rate and renal sympathetic nerve activity in rats. Am J Physiol 1992; 262(5 Pt 2):H1441-H1448
54. Yamazaki M, Ozono K, Okada T et al. Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells. J Cell Biochem 2010; 111(5):1210-1221
55. Mazzaferro S,PasqualiM,Pirro Get al. The bone and the kidney. Arch Biochem Biophys 2010; 503(1):95-102
56. Keisala T, Minasyan A, Lou YR et al. Premature aging in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 2009; 115(3-5):91-97
57. Chattopadhyay N, Baum M, Bai M et al. Ontogeny of the extracellular calcium-sensing receptor in rat kidney. Am J Physiol 1996; 271(3 Pt 2):F736-F743
58. Biber J, Hernando N, Forster I et al. Regulation of phosphate transport in proximal tubules. Pflugers Arch 2009; 458(1):39-52
59. Moe OW. PiT-2 coming out of the pits. Am J Physiol Renal Physiol 2009;296(4):F689-F690
60. Panda DK, Al Kawas S, Seldin MF et al. 25-hydroxyvitamin D 1alpha-hydroxylase: structure of the mouse gene, chromosomal assignment, and developmental expression. J Bone Miner Res 2001; 16(1):46-56
61. Lai WP, Chau TS, Cheung PY et al. Adaptive responses of 25-hydroxyvitamin D3 1-alpha hydroxylase expression to dietary phosphate restriction in young and adult rats. Biochim Biophys Acta 2003; 1639(1):34-42
62. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95(2):578-585
63. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 2005; 20(7):1295-1298
64. Weber TJ, Liu S,Indridason OS etal. SerumFGF23 levels innormal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18(7):1227-1234
65. Nakatani T, Sarraj B, Ohnishi M et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation ofsystemic phosphate homeostasis. FASEB J2009; 23(2):433-441
66. Jono S, Shioi A, Ikari Y et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006; 24(2):176-181
67. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14(9 Suppl 4):S305-S309
68. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis 2010; 17(4):302-307
69. Martin JE, Sheaff MT. Renal ageing. J Pathol 2007; 211(2):198-205
70. Lerma EV. Anatomic and physiologic changes of the aging kidney. Clin Geriatr Med 2009; 25(3):325-329
71. Chen G, Bridenbaugh EA, Akintola AD et al. Increased susceptibility of aging kidney to ischemic injury: identification of candidate genes changed during aging, but corrected by caloric restriction. Am J Physiol Renal Physiol 2007; 293(4):F1272-F1281
72. Musso CG, Liakopoulos V, Ioannidis I et al. Acute renal failure in the elderly: particular characteristics. Int Urol Nephrol 2006; 38(3-4):787-793
73. Campbell KH, O'Hare AM. Kidney disease in the elderly: update on recent literature. Curr Opin Nephrol Hypertens 2008; 17(3):298-303
74. Hu MC, Bankir L, Michelet S et al. Massive reduction of urea transporters in remnant kidney and brain of uremic rats. Kidney Int 2000; 58(3):1202-1210
75. Tamura K, Suzuki Y, Matsushita M et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 2007; 558(1-3):159-166
76. Peralta CA, Kurella M, Lo JC et al. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens2006; 15(4):361-365
77. Nagase M, Yoshida S, Shibata S et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006;17(12):3438-3446
78. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006; 17(4 Suppl2):S81-S85
79. Kawano K, Hirashima T, Mori S et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41(11):1422-1428
80. Yamagishi T, Saito Y, Nakamura T et al. Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res 2001; 24(6):705-709
81. Ohyama Y, Kurabayashi M, Masuda H et al. Molecular cloning of rat klotho cDNA: markedly decreased expression ofklothoby acute inflammatory stress. Biochem Biophys Res Commun 1998;251(3):920-925
82. Thurston RD, Larmonier CB, Majewski PM et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. Gastroenterology 2010; 138(4):1384-1394
83. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331(7520):810
84. Jiang H, Sakuma S, Fujii Y et al. Tacrolimus versus cyclosporin A: a comparative study onrat renal allograft survival. Transpl Int 1999; 12(2):92-99
85. Gulati S, Prasad N, Sharma RK et al. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008; 23(3):910-913
86. Tang S, Tang AW, Tam MK et al. Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome. Am J Kidney Dis 2003; 42(5):E13-E15
87. Ziolkowski J, Paczek L, Senatorski G et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003; 35(6):2307-2309
88. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4(2):481-508
89. Formica RN Jr, Lorber KM, Friedman AL et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. Transplant Proc 2003; 35(3 Suppl):95S-98S
90. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16(2):520-528
91. Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrol Dial Transplant 2002; 17 Suppl 11:16-19
92. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20(2):388-396
93. Kuro-o M. A potential link between phosphate and aging-lessons from Klotho-deficient mice. Mech Ageing Dev 2010; 131(4):270-275
94. Morishita K, Shirai A, Kubota M et al. The progression of aging in klotho mutant mice can be modified bydietaryphosphorusandzinc. JNutr2001; 131(12):3182-3188
95. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22(4):477-501
96. Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the trade-off hypothesis. Clin J Am Soc Nephrol 2010; 5(9):1710-1716
97. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17(5):1305-1315
98. Palm F, Nangaku M, Fasching A et al. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. Am J Physiol Renal Physiol 2010; 299(2):F380-F386
99. Polichnowski AJ, Jin C, Yang C et al. Role of renal perfusion pressure versus angiotensin II on renal oxidative stress in angiotensin II-induced hypertensive rats. Hypertension 2010; 55(6):1425-1430
100. Yu M, Kim YJ, Kang DH. Indoxyl Sulfate-Induced Endothelial Dysfunction in Patients with Chronic Kidney Disease via an Induction of Oxidative Stress. Clin J Am Soc Nephrol 2011: 6(1):30-39
101. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4(10):1551-1558
102. Niwa T, Adijiang A, Higuchi Y et al. Indoxyl Sulfate Reduces Klotho Expression and Promotes Senescence in the Kidney ofHypertensive Rats (Abstract). J Am Soc Nephrol 2010; 21:746A
103. Jennings P, Koppelstaetter C, Aydin S et al. Cyclosporine A induces senescence in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007; 293(3):F831-F838
104. Kailong L, Du X, Yani H et al. P53-Rb signaling pathway is involved in tubular cell senescence in renal ischemia/reperfusion injury. Biocell 2007; 31(2):213-223
105. DmitrievaNI, Burg MB. High NaCl promotes cellular senescence. Cell Cycle 2007; 6(24):3108-3113
106. Yang H, Fogo AB. Cell senescence in the aging kidney. J Am Soc Nephrol 2010; 21(9):1436-1439
107. Nakano-Kurimoto R, Ikeda K, Uraoka M et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol 2009; 297(5):H1673-H1684
108. Yang HC, Deleuze S, Zuo Y et al. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009; 20(11):2380-2388
109. Shimizu H, Bolati D, Adijiang A et al. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am J Physiol Cell Physiol 2010; 299(5):C1110-C1117
110. De Oliveira RM. Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett 2006; 580(24):5753-5758
111. Ikushima M, Rakugi H, Ishikawa K et al. Anti-apoptotic and anti-senescence effects ofKlotho on vascular endothelial cells. Biochem Biophys Res Commun 2006; 339(3):827-832
112. Taniyama Y, Morishita R. Does therapeutic angiogenesis overcome CKD? Hypertens Res2010;33(2):114-115
113. Mu W, Long DA, Ouyang X et al. Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am J Physiol Renal Physiol 2009;296(1):F145-F152
114. Westerweel PE, Hoefer IE, Blankestijn PJ et al. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol 2007; 292(4):F1132-F1140
115. Chade AR, Zhu X, Mushin OP et al. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 2006; 20(10):1706-1708
116. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006; 17(4):932-942
117. Nakamura T, Saito Y, Ohyama Y et al. Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 2002; 89(2):149-156
118. Shimada T, Takeshita Y, Murohara T et al. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004; 110(9):1148-1155
119. Fukino K, Suzuki T, Saito Y et al. Regulation of angiogenesis by the aging suppressor gene klotho. Biochem Biophys Res Commun 2002; 293(1):332-337
120. Maekawa Y, Ishikawa K, Yasuda O et al. Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine 2009;35(3):341-346
121. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21(8):1247-1253
122. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21(2):212-222
123. Ardura JA, Rayego-Mateos S, Ramila D et al. Parathyroid hormone-related protein promotes epithelial-mesenchymal transition. J Am Soc Nephrol 2010; 21(2):237-248
124. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112(12):1776-1784
125. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9(7):964-968
126. Iwano M, Plieth D, DanoffTM et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110(3):341-350
127. Iwano M. EMT and TGF-beta in renal fibrosis. Front Biosci (Schol Ed) 2010; 2:229-238
128. Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. AmJNephrol 2010; 31(1):68-74
129. Sato M, Muragaki Y, Saika S et al. Targeted disruption ofTGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112(10):1486-1494
130. Sugiura H, Yoshida T, Kohei J et al. TGF-p Was Upregulated in Renal Fibrosis Model ofKlotho Defect Mouse and Affected Renal Klotho Expression Level (Abstract). J Am Soc Nephrol 2010; 21:376A
131. Doi S, Yorioka N, Kuroo M. Secreted Klotho Protein Counteracts Renal Fibrosis through Inhibiting TGF-b1 Signaling (Abstract). J Am Soc Nephrol 2010; 21:270A
132. Yamamoto K, Loskutoff DJ. The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/ procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol 1997; 151(3):725-734
133. Yamamoto K, Loskutoff DJ, Saito H. Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age. Semin Thromb Hemost 1998; 24(3):261-268
134. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17(11):2999-3012
135. TakeshitaK, Yamamoto K, ItoM etal. Increased expression ofplasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, Klotho mouse. Semin Thromb Hemost 2002; 28(6):545-554
136. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19(2):213-216
137. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N et al. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006; 17(12 Suppl 3):S267-S273
138. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20(7):1453-1464
139. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98(7):905-912
140. Lim K,LuT-S, Zehnder D et al. Development ofKlotho-FGFR1/3 Dependent Resistance to FGF-23 in Human Aortic Smooth Muscle Cells Exposed to Calcifying Stress. J Am Soc Nephrol 2010; 21:140A
141. London GM, Marchais SJ, Guerin AP et al. Contributive factors to cardiovascular hypertrophy in renal failure. Am J Hypertens 1989; 2(11 Pt 2):261S-263S
142. Guerin AP, Pannier B, Marchais SJ et al. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens 2006; 15(2):105-110
143. Cerasola G, Nardi E, Palermo A et al. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: areview. JNephrol 2011; 24(1):1-10
144. Rinat C, Becker-Cohen R, Nir A et al. A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. Nephrol Dial Transplant 2010; 25(3):785-793
145. Edwards NC, Steeds RP, Stewart PM et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009; 54(6):505-512
146. Burrell LM, Johnston CI. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. DrugsAging 1997; 10(6):421-434
147. Achinger SG, Ayus JC. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int 2005; 95 Suppl:S37-S42
148. Mirza MA, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207(2):546-551
149. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77(3):211-218
150. Khan S, Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci 2007; 333(4):201-207
151. Krajisnik T, Olauson H, Mirza MA et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010; 78(10):1024-1032
152. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010; 21(7):1125-1135
153. Hofman-Bang J, Martuseviciene G, Santini MA et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int2010; 78(11):1119-1127
154. Gattineni J, Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010; 25(4):591-601
155. Carter JL, O'Riordan SE, Eaglestone GL et al. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. Nephrol Dial Transplant 2008; 23(11):3554-3565
156. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5(2):286-291
157. FukagawaM, Kazama JJ. FGF23: its role in renal bone disease. Pediatr Nephrol 2006; 21(12):1802-1806
158. Tomida K, Hamano T, Mikami S et al. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in nondiabetic predialysis CKD patients. Bone 2009; 44(4):678-683
159. Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res 2007; 22(2):203-210
160. Kawaguchi H, Manabe N, Miyaura C et al. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 1999; 104(3):229-237
161. Kawaguchi H, Manabe N, Chikuda H et al. Cellular and molecular mechanism of low-turnover osteopenia in the klotho-deficient mouse. Cell Mol Life Sci 2000; 57(5):731-737
162. Shiraki-Iida T, Iida A, Nabeshima Y et al. Improvement of multiple pathophysiological phenotypes of klotho (kl/kl) mice by adenovirus-mediated expression of the klotho gene. J Gene Med 2000; 2(4):233-242
163. Segawa H, Yamanaka S, Ohno Y et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 2007; 292(2):F769-F779
164. Sorribas V, Markovich D, Hayes G et al. Cloning of a Na/Pi cotransporter from opossum kidney cells. J Biol Chem 1994; 269(9):6615-6621
165. Ramos AM, Albalate M, Vazquez S et al. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int 2008; 111(Suppl):S88-S93
166. Koizumi T, Murakami K, Nakayama H et al. Role of dietary phosphorus in the progression ofrenal failure. Biochem Biophys Res Commun 2002; 295(4):917-921
167. Tonelli M, Wang W, Hemmelgarn B et al. Phosphate removal with several thrice-weekly dialysis methods in overweight hemodialysis patients. Am J Kidney Dis 2009; 54(6):1108-1115
168. Marshall CB, Pippin JW, Krofft RD et al. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006; 70(11):1962-1973
169. Diamond JR. Reactive oxygen species and progressive glomerular disease. J Lab Clin Med 1994; 124(4):468-469
170. Shih PH, Yen GC. Differential expressions of antioxidant status in aging rats: the role of transcriptional factor Nrf2 and MAPK signaling pathway. Biogerontology 2007; 8(2):71-80
171. Kachiwala SJ, Harris SE, Wright AF et al. Genetic influences on oxidative stress and their association with normal cognitive ageing. Neurosci Lett 2005; 386(2):116-120
172. Yamamoto M, Clark JD, Pastor JV et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005; 280(45):38029-38034
173. Feng R, He W, Ochi H. A new murine oxidative stress model associated with senescence. Mech Ageing Dev 2001; 122(6):547-559
174. Melk A, Schmidt BM, Braun H et al. Effects of donor age and cell senescence on kidney allograft survival. Am J Transplant 2009; 9(1):114-123
175. Yang F, Huang XR, Chung AC et al. Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J Pathol 2010; 221(4):390-401
176. Liang XB, Ma LJ, Naito T et al. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 2006; 17(7):1886-1895
177. Park SY, Song CY, Kim BC et al. Angiotensin II mediates LDL-induced superoxide generation in mesangial cells. Am J Physiol Renal Physiol 2003; 285(5):F909-F915
178. Stevenson KM, Edgley AJ, Bergstrom G et al. Angiotensin II infused intrarenally causes preglomerular vascular changes and hypertension. Hypertension 2000; 36(5):839-844
179. Peters H, Border WA, Noble NA. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int 2000; 57(4):1493-1501
180. Zhou Q, Lin S, Tang R et al. Role of Fosinopril and Valsartan on Klotho Gene Expression Induced by Angiotensin II in Rat Renal Tubular Epithelial Cells. Kidney Blood Press Res 2010; 33(3):186-192
181. Narumiya H, Sasaki S, Kuwahara N et al. HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Cardiovasc Res 2004; 64(2):331-336
182. Rosner MH. Urinary biomarkers for the detection of renal injury. Adv Clin Chem 2009; 49:73-97
183. PercoP,WilflingsederJ,BernthalerAetal. Biomarker candidates for cardiovascular disease andbone metabolism disorders in chronic kidney disease: a systems biology perspective. J Cell Mol Med 2008; 12(4):1177-1187
184. Kovesdy CP, Kalantar-Zadeh K. Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 2009; 14(4):408-415
185. Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 2010; 17(6):469-479
186. Guh JY. Proteinuria versus albuminuria in chronic kidney disease. Nephrology (Carlton) 2010; 15(Suppl 2):53-56
187. Bokenkamp A, Domanetzki M, Zinck R et al. Reference values for cystatin C serum concentrations in children. PediatrNephrol 1998; 12(2):125-129
188. Galteau MM, Guyon M, Gueguen R et al. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001; 39(9):850-857
189. Shlipak MG, Wassel Fyr CL, Chertow GM et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006; 17(1):254-261
190. Djousse L, Kurth T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 2008; 155(1):82-86
191. Drechsler C, Krane V, Winkler K et al. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009; 76(5):567-575
192. Saraheimo M, Forsblom C, Thorn L et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008; 31(6):1165-1169
193. Baggio B, Gambaro G, Briani G et al. Urinary excretion of glycosaminoglycans and brush border and lysosomal enzymes as markers of glomerular and tubular involvement in kidney diseases. Contrib Nephrol 1984; 42:107-110
194. Ryu S, Chang Y, Kim DI et al. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 2007; 53(1):71-77
195. Dhaun N, Lilitkarntakul P, Macintyre IM et al. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 2009; 296(6):F1477-F1483
196. Cottone S, Mule G, Guarneri M et al. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant 2009; 24(2):497-503
197. Chang HY, Tung CW, Lee PH et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 2010; 339(6):509-515
198. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009; 18(6):526-530
199. Madero M, Sarnak MJ, Wang X et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009; 53(5):796-803
200. Yilmaz MI, Sonmez A, Saglam M et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78(7):679-685
201. Appledorn DM, Seregin S, Amalfitano A. Adenovirus vectors for renal-targeted gene delivery. Contrib Nephrol 2008; 159:47-62
202. Imai E. Gene therapy approach in renal disease in the 21st century. Nephrol Dial Transplant2001; 16 Suppl 5:26-34
203. Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009; 54(4):810-817
204. Brown AJ, Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab 2007; 3(2):134-144
205. Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res 2007; 22(Suppl 2):V91-V94
206. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int 2010; 78(2):146-151
207. Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005; 18(4):315-321
208. Chen HH, Tarng DC, Lee KF et al. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol 2008; 21(4):543-549
209. Coles GA, Cavill I. Erythropoiesis in the anaemia of chronic renal failure: the response to CAPD. Nephrol DialTransplant 1986; 1(3):170-174
210. Dharmarajan TS, Widjaja D. Erythropoiesis-stimulating agents in anemia: use and misuse. J Am Med Dir Assoc 2009; 10(9):607-616
211. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281(10):6120-6123
212. Hall RL, Wilke WL, Fettman MJ. Captopril slows the progression of chronic renal disease in partially nephrectomized rats. Toxicol Appl Pharmacol 1985; 80(3):517-526
213. Brezis M, Greenfeld Z, Shina A et al. Angiotensin II augments medullary hypoxia and predisposes to acute renal failure. Eur J Clin Invest 1990; 20(2):199-207
214. Hall JE. The renin-angiotensin system: renal actions and blood pressure regulation. Compr Ther 1991; 17(5):8-17
215. Nabokov A, Amann K, Gassmann P et al. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 1998; 13(1):173-176
216. Tojo A, Onozato ML, Kobayashi N et al. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002; 40(6):834-839
217. Muller DN, Mullally A, Dechend R et al. Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 2002; 40(6):840-846
218. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003; 284(4):F863-F869
219. Remuzzi G, Perico N, Macia M et al. The role of renin-angiotensin- aldosterone system in the progression of chronic kidney disease. Kidney Int 2005; 99(Suppl):S57-S65
220. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005; 65 Suppl 2:29-39
221. Mizuno M, Sada T, Kato M et al. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes. J Cardiovasc Pharmacol 2006; 48(4):135-142
222. Lebel M, Rodrigue ME, Agharazii M et al. Antihypertensive and renal protective effects of renin-angiotens in system blockade in uremic rats treated with erythropoietin. Am J Hypertens 2006; 19(12):1286-1292
223. Negri AL. The klotho gene: a gene predominantly expressed in the kidney is a fundamental regulator of aging and calcium/phosphorus metabolism. J Nephrol 2005; 18(6):654-658
224. Kuwahara N, Sasaki S, Kobara M et al. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol 2008; 123(2):84-90
225. Wang X, LiuX, Zhan Y et al. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation. J Pharmacol Exp Ther 2010; 334(3):820-829
226. Zhang H, Li Y,FanY et al. Klotho is a target gene ofPPAR-gamma. Kidney Int 2008; 74(6):732-739
227. Zhang R, Zheng F. PPAR-gamma and aging: one link through klotho? Kidney Int 2008; 74(6):702-704
228. Lopez-Hernandez FJ, Lopez-Novoa JM. Potential utility of PPARalpha activation in the prevention of ischemic and drug-induced acute renal damage. Kidney Int 2009; 76(10):1022-1024
229. Li S, Nagothu KK, Desai V et al. Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury. Kidney Int 2009; 76(10):1049-1062
230. Rakugi H, Matsukawa N, Ishikawa K et al. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine 2007; 31(1):82-87
231. Shah SV, Baliga R, Rajapurkar M et al. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18(1):16-28
232. Sugiura H, Yoshida T, Mitobe M et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25(1):60-68